Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and pr… Read more
Jiangsu Cowin Biotech Co. Ltd. A (688426) - Net Assets
Latest net assets as of June 2025: CN¥1.43 Billion CNY
Based on the latest financial reports, Jiangsu Cowin Biotech Co. Ltd. A (688426) has net assets worth CN¥1.43 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.57 Billion) and total liabilities (CN¥145.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.43 Billion |
| % of Total Assets | 90.77% |
| Annual Growth Rate | 37.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 97.58 |
Jiangsu Cowin Biotech Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how Jiangsu Cowin Biotech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jiangsu Cowin Biotech Co. Ltd. A (2020–2024)
The table below shows the annual net assets of Jiangsu Cowin Biotech Co. Ltd. A from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.49 Billion | -11.50% |
| 2023-12-31 | CN¥1.68 Billion | -6.26% |
| 2022-12-31 | CN¥1.79 Billion | +226.79% |
| 2021-12-31 | CN¥548.26 Million | +32.25% |
| 2020-12-31 | CN¥414.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Cowin Biotech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 337.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.48 Billion | 101.12% |
| Total Equity | CN¥1.47 Billion | 100.00% |
Jiangsu Cowin Biotech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Jiangsu Cowin Biotech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quess Corp Limited
NSE:QUESS
|
$108.52 Million |
|
XSpring Capital Public Company Limited
BK:XPG
|
$108.52 Million |
|
Taaleri Oyj
HE:TAALA
|
$108.53 Million |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
$108.54 Million |
|
Ca Toulouse 31 CCI
PA:CAT31
|
$108.47 Million |
|
Hap Seng Plantations Holdings Bhd
KLSE:5138
|
$108.46 Million |
|
CARASENT ASA NK 1332
F:C34
|
$108.35 Million |
|
Taisun Enterprise Co Ltd
TW:1218
|
$108.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Cowin Biotech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,663,673,678 to 1,465,785,418, a change of -197,888,260 (-11.9%).
- Net loss of 157,209,230 reduced equity.
- Dividend payments of 3,900,467 reduced retained earnings.
- Other factors decreased equity by 36,778,563.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-157.21 Million | -10.73% |
| Dividends Paid | CN¥3.90 Million | -0.27% |
| Other Changes | CN¥-36.78 Million | -2.51% |
| Total Change | CN¥- | -11.89% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Cowin Biotech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.61x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥4.94 | CN¥22.77 | x |
| 2021-12-31 | CN¥6.54 | CN¥22.77 | x |
| 2022-12-31 | CN¥15.86 | CN¥22.77 | x |
| 2023-12-31 | CN¥14.82 | CN¥22.77 | x |
| 2024-12-31 | CN¥13.03 | CN¥22.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Cowin Biotech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -124.89%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.10x
- Recent ROE (-10.73%) is below the historical average (8.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 26.12% | 46.38% | 0.49x | 1.14x | CN¥66.76 Million |
| 2021 | 22.95% | 37.18% | 0.52x | 1.18x | CN¥71.02 Million |
| 2022 | 8.95% | 30.53% | 0.27x | 1.10x | CN¥-18.78 Million |
| 2023 | -5.07% | -49.26% | 0.09x | 1.10x | CN¥-250.78 Million |
| 2024 | -10.73% | -124.89% | 0.08x | 1.10x | CN¥-303.79 Million |
Industry Comparison
This section compares Jiangsu Cowin Biotech Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Cowin Biotech Co. Ltd. A (688426) | CN¥1.43 Billion | 26.12% | 0.10x | $108.49 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |